Rigel Pharmaceuticals Inc (RIGL) stock
Close on Nov 11, 2026Market cap $831.63MP/E 2.9Yield –
Rigel Pharmaceuticals Inc grew revenue 2.2% to $288.21M over the twelve months to Sep 30, 2026. Operating income fell 36.3% to $75.74M, moving the operating margin from 42.2% to 26.3%. At the latest close the market valued the company at $831.63M, 2.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $831.63M
- P/E ratio
- 2.9
- Price to sales
- 2.89
- Price to book
- 1.87
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $288.21M
- Net income
- $307.19M
- EPS, diluted
- $15.23
- Book value per share
- $21.78
- Diluted shares
- 20M
Trading
- Next earnings
- Mar 2, 2027 (estimated, during market hours)
- Previous close
- $43.91
- Open
- $44.00
- Day's range
- $43.48 – $44.63
- Volume
- 140,679
- Average volume (20 days)
- 253,705
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $24.95 – $52.60
- RSI (14 days)
- 43.8
- Volatility (1 year)
- 55.6%
- Relative volume
- 0.50×
- WACC
- 10.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RIGL | S&P 500 | Difference | RIGL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.3% | -2.4% | −6.9 pts | ||
| 3 months | +5.9% | -1.2% | +7.1 pts | ||
| Year to date | +3.9% | +12.3% | −8.3 pts | ||
| 1 year | +17.3% | +12.4% | +4.9 pts | ||
| 3 years | +442.9% | +78.8% | +364.1 pts | +75.8% | +21.4% |
| 5 years | +39.6% | +75.2% | −35.6 pts | +6.9% | +11.9% |
| 10 years | +39.1% | +311.1% | −272.0 pts | +3.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rigel Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About Rigel Pharmaceuticals
Pharmaceutical Preparations
The company is a biotechnology business that develops and provides small-molecule therapies for patients with hematologic disorders and cancer. Its commercial portfolio features three approved drugs: fostamatinib, an oral kinase inhibitor for adults with chronic immune thrombocytopenia; olutasidenib, a targeted therapy for relapsed or refractory acute myeloid leukemia; and pralsetinib, a kinase inhibitor for metastatic non-small cell lung cancer and advanced thyroid cancer. Its primary end customers are hematology and oncology patients, reached via wholesale distributors, specialty pharmacies, and healthcare providers.
Company profile, executives and historyRigel Pharmaceuticals stock: common questions
What is Rigel Pharmaceuticals's stock price?
RIGL closed at $44.52 on Nov 11, 2026, up 1.39% on the day. Over the past 52 weeks it traded between $24.95 and $52.60.
What is Rigel Pharmaceuticals's market cap?
Rigel Pharmaceuticals was worth $831.63M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RIGL's P/E ratio?
RIGL trades at 2.9 times earnings, based on diluted earnings per share of $15.23 over the twelve months to Sep 30, 2026.
How much revenue does Rigel Pharmaceuticals make?
Rigel Pharmaceuticals reported revenue of $288.21M for the twelve months to Sep 30, 2026, up 2.2% from a year earlier.
Does Rigel Pharmaceuticals pay a dividend?
No. Rigel Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Rigel Pharmaceuticals report earnings next?
Rigel Pharmaceuticals is expected to report Q4 FY2026 results on Mar 2, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RIGL stock performed over the past year?
Including dividends, RIGL returned +17.3% over the past year, against +12.4% for the S&P 500.
How many RIGL shares are sold short?
3M shares were sold short at the latest FINRA report, 14.03% of the float, or 12.9 days of average trading volume.
Who are Rigel Pharmaceuticals's competitors?
Companies most similar to Rigel Pharmaceuticals by business, industry and size include SNDX, PBYI, NUVB, AGIO, URGN.
See a number that looks wrong?